New shot shows promise for tough eczema in early trial
NCT ID NCT05549947
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new drug called SHR-1819 in 158 adults with moderate to severe atopic dermatitis (a type of eczema). Participants received one of three doses of the drug or a placebo. The main goal was to see if the drug could reduce eczema severity by at least 75% after 16 weeks. The trial is now complete, and results will help decide if larger studies are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-1819 injection
What this could lead to
If successful, this could lead to a new treatment option for people with moderate to severe atopic dermatitis, helping to control skin inflammation and itching.
What could go wrong
This is an early Phase 2 trial with only 158 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Sub-Hospital of Fudan University
Shanghai, Shanghai Municipality, 200040, China